Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08NMV
|
||||
| Former ID |
DNCL003697
|
||||
| Drug Name |
Ixekizumab
|
||||
| Synonyms |
LY2439821
|
||||
| Drug Type |
Monoclonal antibody
|
||||
| Company |
Eli Lilly
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-17 | Target Info | Modulator | [532056], [532704] | |
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Interleukin signaling pathway | ||||
| Pathway Interaction Database | IL27-mediated signaling events | ||||
| IL23-mediated signaling events | |||||
| References | |||||
| Ref 523694 | ClinicalTrials.gov (NCT01474512) A Phase 3 Study in Participants With Moderate to Severe Psoriasis. U.S. National Institutes of Health. | ||||
| Ref 542543 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7541). | ||||
| Ref 889440 | 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. doi: 10.1038/nrd.2017.14. | ||||
| Ref 532056 | Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5. | ||||
| Ref 532704 | A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response totumor necrosis factor inhibitors. Arthritis Rheumatol. 2014 Jul;66(7):1693-704. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.